Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002100119-26-000022
Filing Date
2026-04-28
Accepted
2026-04-28 11:32:20
Documents
1
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5731
  Complete submission text file 0002100119-26-000022.txt   7683
Mailing Address 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS CAMBRIDGE United Kingdom CB2 0AA
Business Address 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS CAMBRIDGE United Kingdom CB2 0AA 011 44 20 7304 5000
ASTRAZENECA PLC (Subject) CIK: 0000901832 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-55247 | Film No.: 26905011
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 100 VANGUARD BLVD MALVERN PA 19355
Business Address 100 VANGUARD BLVD MALVERN PA 19355 610-669-6148
VANGUARD CAPITAL MANAGEMENT LLC (Filed by) CIK: 0002100119 (see all company filings)

EIN.: 392877419 | State of Incorp.: PA | Fiscal Year End: 1231
LEI: 529900ZEWTRLEJ6XE960
Type: SCHEDULE 13G